United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - flurazepam hydrochloride (unii: 756rdm536m) (flurazepam - unii:ihp475989u) - flurazepam hydrochloride 15 mg - flurazepam hydrochloride capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. flurazepam hydrochloride capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration. since insomnia is often transient and intermittent short-term use is usually sufficient. prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. flurazepam hydrochloride capsules are contraindicated in patients with known hypersensitivity to the drug. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated wi

United States - English - NLM (National Library of Medicine)

rebel distributors corp - flurazepam hydrochloride (unii: 756rdm536m) (flurazepam - unii:ihp475989u) - flurazepam hydrochloride 30 mg - flurazepam hydrochloride capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. flurazepam hydrochloride capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration. since insomnia is often transient and intermittent short-term use is usually sufficient. prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. flurazepam hydrochloride capsules are contraindicated in patients with known hypersensitivity to the drug. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated wi

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - flurazepam hydrochloride (unii: 756rdm536m) (flurazepam - unii:ihp475989u) - flurazepam hydrochloride 30 mg - flurazepam hydrochloride capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. flurazepam hydrochloride capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration. since insomnia is often transient and intermittent short-term use is usually sufficient. prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. flurazepam hydrochloride capsules are contraindicated in patients with known hypersensitivity to the drug. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated wi

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - flurazepam hydrochloride (unii: 756rdm536m) (flurazepam - unii:ihp475989u) - flurazepam hydrochloride 30 mg - flurazepam hydrochloride capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. flurazepam hydrochloride capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration. since insomnia is often transient and intermittent short-term use is usually sufficient. prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. flurazepam hydrochloride capsules are contraindicated in patients with known hypersensitivity to the drug. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated wi

United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - reteplase (unii: dqa630rie9) (reteplase - unii:dqa630rie9) - retavase is indicated for use in acute st-elevation myocardial infarction (stemi) to reduce the risk of death and heart failure. limitation of use: the risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose stemi puts them at low risk for death or heart failure. because thrombolytic therapy increases the risk of bleeding, retavase is contraindicated in the following situations: - active internal bleeding - recent stroke - intracranial or intraspinal surgery or serious head trauma within 3 months - intracranial conditions that increase the risk of bleeding (e.g. neoplasms, arteriovenous malformation, or aneurysms) - bleeding diathesis - current severe uncontrolled hypertension risk summary limited published data with retavase use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes.  in animal reproduction studies, reteplase administered to pregnant rabbits resulted in hemorrhaging in the genital tract, leading to abortions i

Australia - English - Department of Health (Therapeutic Goods Administration)

retscanner pty ltd - 58713 - automated retinopathy analysis system application software - automated machine learning screening system application software intended to analyze images and classify the images based on the presence of suspicous patterns in the image that could be lesions typical from pathologies such as diabetic retinopathy. the technology receives colour fundus images as input and outputs a label saying if the image has lesions or not (and from the images, infers a positive or negative result for the patient).

Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 36545 - basic power supply - a device designed to receive alternating-current energy (ac-power) from a mains electricity power line and deliver one or more regulated direct-current outputs to supply devices with electrical energy.

Australia - English - Department of Health (Therapeutic Goods Administration)

care essentials pty ltd - 35626 - telemetry system, electroencephalograph - the device acquires eeg through electrodes attached to the patient's scalp and transmits the waveforms wirelessly to an electroencephalograph. by using eeg headset with an electroencephalograph, the headset outputs accurate eeg waves (diagnostic information of brain functions) to the electroencephalograph

Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 36273 - ultrasonic surgical system generator - intended for use with the ultrasonic surgical system generator to control settings level of system functional outputs.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - tablets film-coated - 75mg+ 100mg